Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s ...

Merck receives two positive EU CHMP opinions for Keytruda for SC administration and for new indication for earlier-stage head and neck cancer: Rahway, New Jersey Saturday, Septemb ...

Plasma p-tau217 testing can help detect preclinical Alzheimer disease in cognitively unimpaired adults. Using it as a ...

AstraZeneca's immunotherapy Imfinzi is the first drug therapy to be recommended for routine NHS use as a treatment for ...

There is frustration bubbling over water and sewer bills in St. Louis. Some residents say they’re being charged for water ...

Which is why, over the past month, I’ve been road-testing and curating the ultimate edit of chocolate brown nail polishes.

After a strategy revamp Noxopharm is pursuing a clinical program targeting inflammation, notably the painful condition skin ...

Neos S&P 500 High Income ETF (SPYI) is overrated, offering high yield but limited downside protection and lower upside than ...

There is no cure for dry AMD, but if vision loss progresses, your doctor may suggest devices for low vision, such as telescopes, magnifiers, or phones with large print. An augmented reality visor has ...

Rahway: Merck, Daiichi Sankyo have announced that Raludotatug deruxtecan (R-DXd) has received Breakthrough Therapy ...

US FDA grants breakthrough therapy designation to Daiichi Sankyo & Merck’s raludotatug deruxtecan for patients with CDH6 expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube ...

Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant ...